Vascular targeting tumor therapy: Non-invasive contrast enhanced ultrasound for quantitative assessment of tumor microcirculation

Cancer Biology and Therapy

Volumn 9, Issue 10, 2010, Pages 792-800

  Eichhorn, Martin E ^a   Klotz, L V ^a   Luedemann, S ^a   Strieth, S ^a   Kleespies, A ^a   Preissler, G ^a   Lindner, M ^b   Jauch, K W ^a   Reiser, M F ^a   Clevert, D A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Asklepios Fachkliniken München Gauting ^*  (Germany)

Author keywords

CEUS; Intravital microscopy; Microbubbles; Microcirculation; Tumor imaging; Ultrasound; Vascular targeting; ZD6126

Indexed keywords

CD31 ANTIGEN; N ACETYLCOLCHINOL PHOSPHATE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; DIAGNOSTIC AGENT; N ACETYLCOCHINOL O PHOSPHATE; N-ACETYLCOCHINOL-O-PHOSPHATE; ORGANOPHOSPHORUS COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD FLOW VELOCITY; CANCER GROWTH; CONTRAST ENHANCED ULTRASONOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ECHOGRAPHY; ERYTHROCYTE; FLUORESCENCE MICROSCOPY; HAMSTER; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTRAVITAL FLUORESCENCE MICROSCOPY; LEWIS CARCINOMA; MALE; MELANOMA; MICROBUBBLE; MICROCIRCULATION; MICROVASCULATURE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; SKINFOLD; SUBCUTANEOUS TISSUE TUMOR; TISSUE PERFUSION; TUMOR VASCULARIZATION; TUMOR BLOOD FLOW; ANIMAL; C57BL MOUSE; COLOR ULTRASOUND FLOWMETRY; DRUG EFFECT; EVALUATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; CRICETINAE; MALE; MICE; MICE, INBRED C57BL; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 77953715887     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
3. Denekamp J. Vascular endothelium as the vulnerable element in tumors. Acta Radiol Oncol 1984; 23:217-25. (Pubitemid 15072794)
4. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62:7247-53.
5. Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, Hill SA. Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 2008; 81:12-20.
6. Kleespies A, Kohl G, Friedrich M, Ryan AJ, Barge A, Jauch KW, et al. Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models. Neoplasia 2005; 7:957-66.
7. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma and soft tissue sarcoma. Clin Cancer Res 2003; 9:1648-55.
8. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003; 89:8-14.
9. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 1998; 77:1-10.
10. Asaishi K, Endrich B, Götz A, Messmer K. Quantitative analysis of microvascular structure and function in the amelanotic melanoma A-Mel-3. Cancer Res 1981; 41:1898-904. (Pubitemid 11114593)
11. Baker M, Wayland H. On-line volume flow rate and velocity profile measurement for blood in microvessels. Microvasc Res 1974; 7:131-43.
12. Stieger SM, Bloch SH, Foreman O, Wisner ER, Ferrara KW, Dayton PA. Ultrasound assessment of angiogenesis in a matrigel model in rats. Ultrasound Med Biol 2006; 32:673-81.
13. Ko EY, Lee SH, Kim HH, Kim SM, Shin MJ, Kim N, et al. Evaluation of tumor angiogenesis with a second-generation US contrast medium in a rat breast tumor model. Korean J Radiol 2008; 9:243-9.
14. Lucidarme O, Nguyen T, Kono Y, Corbeil J, Choi SH, Varner J, et al. Angiogenesis model for ultrasound contrast research: exploratory study. Acad Radiol 2004; 11:4-12.
15. McCarville MB, Streck CJ, Dickson PV, Li CS, Nathwani AC, Davidoff AM. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 2006; 240:73-81.
16. Willmann JK, Lutz AM, Paulmurugan R, Patel MR, Chu P, Rosenberg J, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008; 248:936-44.
17. Willmann JK, Cheng Z, Davis C, Lutz AM, Schipper ML, Nielsen CH, et al. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008; 249:212-9.
18. Lee DJ, Lyshchik A, Huamani J, Hallahan DE, Fleischer AC. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med 2008; 27:855-66.
19. Lyshchik A, Fleischer AC, Huamani J, Hallahan DE, Brissova M, Gore JC. Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med 2007; 26:1575-86.
20. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002; 2:266-76. (Pubitemid 37328780)
21. Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment. APMIS 2008; 116:695-715.
22. Galie M, D'Onofrio M, Montani M, Amici A, Calderan L, Marzola P, et al. Tumor vessel compression hinders perfusion of ultrasonographic contrast agents. Neoplasia 2005; 7:528-36.
23. Niermann KJ, Fleischer AC, Huamani J, Yankeelov TE, Kim DW, Wilson WD, et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 2007; 26:749-56.